Open Access Open Access  Restricted Access Subscription or Fee Access

Vitamin-Aspirin-Prednisolone Therapy for Miscarriage Associated with Anticardiolipin Antibody: Clinical Study

Yong-Chol Hong, Mi-Yong Paek, Hye-Son Jon, Hyon-Saeng Ju, Un-Hyang Pak


Objective: To find pathogenesis of miscarriage associated with anticardiolipin antibody and to make reasonable therapy for the diseases. Methods: Blood coagulation findings, malondialdehyde volume are evaluated and those variations were observed with Vitamin–Aspirin–Prednisolone therapy. And clinical and laboratory findings, pregnancy outcomes were analyzed and relationship between medicine combined therapy and other factors (ages, attack period of disease, miscarriage times, and body mass index) is observed. Results: In anticardiolipin antibody positive group APTT and PT were 36.5  2.4s and 15.4  1.1s, respectively, Fbg was 229.2  14.4 mg/dl, FDP was 11.7  1.6g/mL, PAR was 82.3  2.5%, malondialdehyde volume was 8.71  0.43 nmoL/ml. In treatment application 20 days Fbg was 302.0  16.3 mg/dl, FDP was 6.2  1.2g/mL, malondialdehyde volume was 6.73  0.66 nmoL/ml. In treatment pause 20 days PAR was 81.4  3.6%. In study group, abortion rate was 10.0%, term labor rate and pregnancy maintenance rate were 85.0% and 90.0%, respectively, and preterm labor rate was 5.0%. In miscarriage times 3  group effective ratio depended on miscarriage time in medicine combined therapy was 42.9%. In body mass index, 24.1  group effective ratio depended on body mass index in medicine combined therapy was 42.9%. Conclusion: In anticardiolipin antibody positive patients, coagulation and platelet system were activated and malondialdehyde volume was increased. And, then, it was reasonable to repeat application for 20 days and pause for 10 days of VAP therapy.


Anticardiolipin antibody, miscarriage, vitamin–aspirin–prednisolone therapy Platelets, antibody

Full Text:



Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol. 2012; 120 (6): 1514–1521. doi: 10.1097/01.AOG.0000423816.39542.0f, PMID 23168789.

Lockwood CJ, Schur PH. Obstetrical manifestations of the antiphospholipid syndrome, Vol. 4. Wellesley, MA, USA: UpToDate; 2012.

American College of Obstetricians and Gynecologists Committee on Practice Bulletins Obstetrics. ACOG Practice Bulletin No. 118. Obstet Gynecol. 2011; 117 (1): 192–199. doi: 10.1097/AOG.0b013e31820a61f9, PMID 21173671.

Schneider AS, Szanto PA. Pathology. Wolters Kluwer. Lippincott Williams & Wilkins; 2014.

Hoffman BL, Schorge JO, Schaffer JI, Halvorson LM, Bradshaw KD, Cunningham FG. Williams gynecology. New York, NY, USA: McGraw-Hill Companies; 2012.

Bermas BL, Erkan D, Schur PH. Clinical manifestations of the antiphospholipid syndrome. Vol. 8. Wellesley, MA, USA: UpToDate; 2012.

Bermas BL, Erkan D, Schur PH. Diagnosis of the antiphospholipid syndrome, Vol. 7. Wellesley, MA, USA: UpToDate; 2012.

Bermas BL, Schur PH, Kaplan AA. Treatment of the antiphospholipid syndrome, Vol. 6. Wellesley, MA, USA: UpToDate; 2012.

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74 (6):1011–1018. doi: 10.1136/annrheumdis-2013- 204838, PMID 24464962.

Sakala EP. Obstetrics and gynecology: lecture notes. Fort Lauderdale, FL, USA: Kaplan Publishing Medical; 2016.

Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM et al. Williams obstetrics, 25th ed., Vol. 2236. New York, NY, USA: McGraw-Hill; 2018.

Landon MB, Galan HL, Jauniaux ERM, Driscoll DA, Berghella V, Grobman WA et al. Gabbe’s obstetrics essentials: normal and problem pregnancies. Amsterdam, The Netherlands: Elsevier; 2019.

Moutsopoulos HM, Vlachoyiannopoulos PG. Antiphospholipid syndrome: Harrison’s Principles of Internal Medicine. 19th ed. New York, NY, USA: McGraw-Hill; 2015.

Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010; 12 (1): 45–52. doi: 10.1007/s11926-009-0072-7, PMID 20425533.

Bu C, Gao L, Xie W, Zhang J, He Y, Cai G, et al. Beta2-glycoprotein 1 is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum. 2009; 60 (2): 559–568. doi: 10.1002/art.24262, PMID 19180513.

Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368 (11): 1033–1044. doi: 10.1056/NEJMra1112830, PMID 23484830.

Bermas BL, Schur PH. Pathogenesis of the antiphospholipid syndrome, Vol. 12. Wellesley, MA, USA: UpToDate; 2011.

Wu S, Stephenson MD. Obstetrical antiphospholipid syndrome. Semin Reprod Med. 2006; 24 (1): 40–53. doi: 10.1055/s-2006-931800, PMID 16418977.

Alves JD, Mason LJ, Ames PRJ, Chen PP, Rauch J, Levine JS et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford). 2005; 44 (10): 1238–1244.

Valesini G, Alessandri C. New facet of antiphospholipid antibodies. Annals of the New York Acad Sci. 2005; 1051: 487–497.

Ruchko MV, Gorodnya OM, Pastukh VM, Swiger BM, Middleton NS, Wilson GL et al. Hypoxia- induced oxidative base modifications in the VEGF hypoxia-response element are associated with transcriptionally active nucleosomes. Free Radic Biol Med. 2009; 46 (3): 352–359. doi: 10.1016/j.freeradbiomed.2008.09.038, PMID 18992807.

Gong Y, Yi M, Fediuk J, Lizotte PP, Dakshinamurti S. Hypoxic neonatal pulmonary arterial myocytes are sensitized to ROS-generated 8-isoprostane. Free Radic Biol Med. 2010; 48 (7): 882– 894. doi: 10.1016/j.freeradbiomed.2010.01.009, PMID 20079425.


  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: Journal of Medical Science and Technology

This Journal archive has been shifted to: